We are building a first-in-class drug development pipeline aimed at reinvigorating the immune system to combat cancer and inflammatory diseases.
OUR APPROACH
Vigeo is currently developing therapies that activate the production of TSP-1, a naturally occurring potent immune system regulatory protein. TSP-1 has been shown to attack cancer cells and reduce inflammation at the cellular level.
Our clinical
trials
We are currently enrolling patients the Phase 3 registration ready AGILE Study (NCT03970447) sponsored by Global Coalition for Adaptive Research (GCAR).
Latest News
March 26, 2024
Vigeo Therapeutics to Present at the 2024 Glioblastoma Drug Development Summit in Boston Massachusetts
July 13, 2023
Vigeo Therapeutics Provides Clinical Update on VT1021 Treatment of GBM Expansion Patient
June 02, 2023